Start with Methylphenidate (MPH)
For an adult female with poor CYP2D6 metabolism, start with methylphenidate at 5 mg, as it is not metabolized by CYP2D6 and her genetic profile will not affect its efficacy or tolerability. 1
Why Methylphenidate is the Optimal Choice
Methylphenidate is metabolized primarily by carboxylesterase 1 (CES1), not CYP2D6 2. This makes it the ideal first-line stimulant for your patient because:
- Her poor CYP2D6 metabolism is irrelevant to methylphenidate's pharmacokinetics
- No dose adjustments needed based on her genetic profile
- Standard titration protocols apply without concern for altered drug metabolism
In contrast, amphetamine formulations (dextroamphetamine, mixed amphetamine salts) can be affected by CYP2D6 inhibitors, which may increase amphetamine levels 3. While the clinical significance remains somewhat unclear, starting with a medication unaffected by her known metabolic deficiency is the safer, more predictable approach.
Specific Dosing Algorithm for Adults
Week 1: Start 5 mg MPH in the morning
Week 2: Increase to 10 mg if no improvement
Weeks 3-4: Titrate upward in 5-10 mg intervals weekly until symptoms controlled 1
- Obtain symptom and side-effect ratings from the patient (and significant other if available) before each dose increase
- Monitor blood pressure and pulse at each visit
- Maximum daily doses for adults typically reach 65 mg total, though some patients require up to 1.0 mg/kg 1
Critical Monitoring Points
- Blood pressure and pulse should be checked quarterly 1
- Document clearly if doses exceed typical ranges, noting that lower doses were inadequate and higher doses produce no problematic side effects (weight loss, blood pressure elevation, agitation) 1
- Consider multiple daily doses to cover her full day, as adults often need more frequent dosing than children
Why NOT Atomoxetine First
While atomoxetine is effective for ADHD, it would be problematic as a first choice for your patient. Atomoxetine is predominantly metabolized by CYP2D6, and poor metabolizers experience up to 10-fold higher drug exposure compared to normal metabolizers at comparable doses 2, 4.
Although CYP2D6 poor metabolizers may show better response rates to atomoxetine 4, they also face significantly increased risk of adverse effects, particularly central nervous system and gastrointestinal side effects 4. This requires more cautious dosing and intensive monitoring—unnecessarily complex when methylphenidate offers equivalent efficacy without these pharmacogenetic concerns.
Alternative Stimulant if Needed
If methylphenidate fails (inadequate response or prohibitive side effects), you can switch to dextroamphetamine or mixed amphetamine salts starting at 2.5 mg 1. Approximately 90% of patients respond when both stimulant classes are tried 1. Her CYP2D6 status may theoretically increase amphetamine exposure if she takes CYP2D6 inhibitors concurrently, but this is a secondary consideration compared to methylphenidate's complete independence from this pathway.